局部进行性胰臟癌市场－全球产业规模、份额、趋势、机会及预测（治疗方法、给药途径、最终用户、地区和竞争格局划分，2021-2031年）

全球局部晚期胰臟癌市场预计将从 2025 年的 9.3873 亿美元成长到 2031 年的 16.8033 亿美元，复合年增长率为 10.19%。

局部晚期胰臟癌 (LAPC) 指的是肿瘤局限于胰臟及其邻近组织，并侵犯主要血管，导致在未进行疾病抑制的情况下无法进行手术切除的恶性肿瘤阶段。全球人口老化加剧以及高解析度诊断成像技术的进步是推动该市场成长的主要因素，这些技术能够早期、准确地检测血管侵犯。此外，新辅助化疗通讯协定的临床应用日益广泛，旨在将无法切除的肿瘤转化为可手术治疗的选择，除了更广泛的技术发展外，也是推动市场成长的重要因素。

儘管取得了这些进展，但由于诊断延迟和疾病本身的侵袭性生物学特性，该领域仍面临着许多重大障碍，严重限制了有效干预的治疗机会。近期统计数据也印证了这项持续的临床挑战：美国癌症协会预测，到2025年，美国将新增约67,440例胰臟癌病例。如此高的发病率，加上疾病的快速进展，为长期治疗方案的维持和市场的持续扩张带来了巨大挑战。

市场驱动因素

对肿瘤学研发投入的增加，正透过加速发现新的治疗靶点，从根本上改变局部晚期胰臟癌的治疗模式。私人机构和慈善机构正积极资助应对长期挑战的项目，例如胰腺癌緻密的间质组织和抗药性，从而推动那些往往被传统资金筹措方式忽视的高风险、高回报研究。例如，2024年8月，卢斯特加滕基金会宣布津贴1,070万美元，用于加速早期检测和药物研发计划，这项资金投入对于将实验性化合物转化为实际临床应用至关重要。

同时，支持性的法规结构和孤儿药资格认定为製药公司提供了重要的商业性奖励，促使其专注于这种高死亡率适应症。这些认定加速了针对治疗选择有限的进行性恶性肿瘤的有前景药物的临床开发，有效降低了市场进入门槛。一个显着的例子是，FDA于2024年10月核准新型RAS标靶药物IMM-1-104孤儿药资格认定，先前数据显示该药物的整体缓解率达40%。鑑于该疾病带来的巨大负担，这些激励措施至关重要：根据欧洲奖励癌症协会2024年的估计，到2025年，全球将有564,930人被诊断出患有胰腺癌。

市场挑战

局部晚期胰臟癌的侵袭性生物学特性，以及确诊时往往已处于晚期的高发生率，构成了阻碍市场成长的重大障碍。由于这种恶性肿瘤通常在无特异性症状的情况下进展，患者就诊时往往已出现广泛的血管侵犯，导致无法即时进行手术治疗，并显着限制了治疗机会。这种限制缩短了药物治疗的疗程，并减少了每位患者的总治疗量。此外，由于疾病进展迅速，即使确诊后，临床病情恶化也常常限制了持续辅助性治疗的机会，从而限制了长期照护週期产生收入。

死亡率统计数据进一步凸显了这个限制，显示建立稳定的患者群体十分困难。根据美国癌症协会估计，2024年美国将有51,750人死于胰臟癌。如此高的死亡率阻碍了患者群体的积累，而这对于显着的市场成长至关重要。因此，与其他存活率较高的肿瘤亚专科相比，患者快速更换限制了长期治疗策略的商业性潜力。

市场趋势

KRAS和NRG1融合基因标靶治疗的出现，透过解决以往被认为「无法治疗」的分子驱动因素，正在重新定义临床治疗。与普通化疗不同，这些药物能够选择性地抑制致癌性讯号，为携带特定突变的患者提供治疗选择。新型RAS选择性抑制剂展现持久的疗效，充分体现了这种精准性。例如，2024年10月，Revolution Medicines公司报告称，其药物RMC-6236在既往接受过治疗且携带RAS突变的胰腺导管腺癌患者中，实现了14.5个月的中位总生存期，凸显了治疗模式正朝着个体化方向发展，以改善不同分子亚型患者的生存结局。

同时，肿瘤电场治疗（TTFields）技术的进步带来了一种非侵入性治疗方法，它能在不引起全身毒性的情况下干扰癌细胞分裂。这项技术正越来越多地与标准化疗联合应用，以提高无法手术切除病例的疗效，近期数据显示生存率的提高也证实了这一点。根据Novocure公司于2024年12月公布的III期PANOVA-3试验结果，接受TTFields合併化疗的患者中位总生存期为16.20个月，而仅接受化疗的患者中位总生存期为14.16个月。这确立了基于器械的治疗方法作为现代多模式治疗方法的重要组成部分的地位。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球局部进行性胰臟癌市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依治疗方法（化疗、免疫疗法、分子标靶疗法、放射线治疗、手术）
  • 给药途径（口服、注射、其他）
  • 按最终使用者（医院/诊所、门诊护理中心、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美局部进行性胰臟癌市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲局部进行性胰臟癌市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区局部进行性胰臟癌市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲局部进行性胰臟癌市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲局部进行性胰臟癌市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球局部进行性胰臟癌市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Glaxosmithkline Plc
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Getwell
• Ipsen Biopharmaceuticals, Inc.
• Novartis Pharmaceuticals Corporation
• Pfizer Inc.
• Bayer HealthCare Pharmaceuticals, Inc.
• Genentech USA, Inc.
• AstraZeneca Plc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Locally Advanced Pancreatic Cancer Market is projected to expand from USD 938.73 Million in 2025 to USD 1680.33 Million by 2031, registering a compound annual growth rate of 10.19%. Locally Advanced Pancreatic Cancer (LAPC) is defined as a malignancy stage where the tumor remains confined to the pancreas and immediate structures but encases major blood vessels, rendering it surgically unresectable without prior downstaging. The market is chiefly sustained by the growing global geriatric population and advancements in high-resolution diagnostic imaging, which facilitate earlier and more accurate detection of vascular involvement. Additionally, the rising clinical implementation of neoadjuvant chemotherapy protocols aimed at transforming unresectable tumors into surgical candidates acts as a primary catalyst for market growth, separate from broader technological developments.

Despite these advancements, the sector encounters significant hurdles due to late-stage diagnoses and the aggressive biological nature of the disease, which severely restricts the therapeutic window for effective intervention. This persistent clinical challenge is supported by recent statistics; the American Cancer Society projects that approximately 67,440 individuals in the United States will be diagnosed with pancreatic cancer in 2025. Such elevated incidence rates, combined with rapid disease progression, create substantial obstacles to maintaining long-term treatment regimens and achieving sustained market expansion.

Market Driver

Increasing investments in oncology research and development are fundamentally transforming the therapeutic landscape for locally advanced pancreatic cancer by driving the discovery of novel therapeutic targets. Private and philanthropic entities are aggressively funding initiatives to address historical challenges related to the disease's dense stroma and drug resistance, enabling high-risk, high-reward studies that traditional funding might bypass. For example, the Lustgarten Foundation announced in August 2024 that it awarded $10.7 million in new grants specifically to accelerate projects focused on early detection and new drug development, a financial commitment essential for advancing experimental compounds into viable clinical options.

Concurrently, supportive regulatory frameworks and Orphan Drug Designations provide critical commercial incentives for pharmaceutical companies to focus on this high-mortality indication. These designations expedite the clinical development of promising agents intended for aggressive malignancies with few options, effectively lowering market entry barriers. A notable example occurred in October 2024, when the FDA granted orphan status to the novel RAS-targeting agent IMM-1-104 following data showing a 40% overall response rate; such incentives are vital given the immense disease burden, with Digestive Cancers Europe estimating in 2024 that 564,930 individuals globally will be diagnosed with pancreatic cancer by 2025.

Market Challenge

The aggressive biological nature of locally advanced pancreatic cancer, combined with frequent late-stage diagnosis, presents a major obstacle that directly impedes market growth. Because the malignancy often develops without specific symptoms, patients frequently present with extensive vascular encasement that precludes immediate surgical options and severely limits the therapeutic window. This constraint shortens the duration for administering pharmaceutical interventions, thereby reducing the total volume of therapeutics used per patient; furthermore, the rapid progression of the disease means that even when identified, the opportunity for sustained neoadjuvant treatment is often curtailed by clinical deterioration, restricting revenue generation from long-term care cycles.

This limitation is further underscored by mortality statistics that highlight the difficulty in establishing a stable patient base. According to the American Cancer Society, an estimated 51,750 deaths were attributed to pancreatic cancer in the United States in 2024. Such high attrition rates prevent the accumulation of a prevalent population necessary to drive significant market growth. Consequently, the rapid turnover within the patient pool limits the commercial potential of prolonged therapeutic strategies compared to other oncology sectors characterized by higher survival rates.

Market Trends

The emergence of KRAS and NRG1 fusion targeted therapies is redefining clinical management by addressing molecular drivers that were previously considered undruggable. Unlike generic chemotherapy, these agents selectively inhibit oncogenic signaling, offering options for patients with specific mutations, a precision exemplified by new RAS-selective inhibitors showing durable activity. For instance, Revolution Medicines reported in October 2024 that their agent RMC-6236 achieved a median overall survival of 14.5 months in patients with previously treated pancreatic ductal adenocarcinoma harboring RAS mutations, highlighting a shift toward personalized interventions that improve survival outcomes in distinct molecular subtypes.

Simultaneously, the advancement of Tumor Treating Fields (TTFields) introduces a non-invasive modality that disrupts cancer cell division without causing systemic toxicity. This technology is increasingly integrated with standard chemotherapy to enhance efficacy in unresectable cases, a validity confirmed by recent data demonstrating survival improvements. According to Novocure's December 2024 announcement regarding the Phase 3 PANOVA-3 trial, patients treated with TTFields plus chemotherapy achieved a median overall survival of 16.20 months compared to 14.16 months for chemotherapy alone, establishing device-based therapeutics as a vital component of modern multimodal care regimens.

Key Market Players

• Glaxosmithkline Plc
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Getwell
• Ipsen Biopharmaceuticals, Inc.
• Novartis Pharmaceuticals Corporation
• Pfizer Inc.
• Bayer HealthCare Pharmaceuticals, Inc.
• Genentech USA, Inc.
• AstraZeneca Plc

Report Scope

In this report, the Global Locally Advanced Pancreatic Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Locally Advanced Pancreatic Cancer Market, By Therapy

• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy
• Surgery

Locally Advanced Pancreatic Cancer Market, By Route of administration

• Oral
• Injectables
• Others

Locally Advanced Pancreatic Cancer Market, By End-User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Locally Advanced Pancreatic Cancer Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Locally Advanced Pancreatic Cancer Market.

Available Customizations:

Global Locally Advanced Pancreatic Cancer Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Locally Advanced Pancreatic Cancer Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery)
  • 5.2.2. By Route of administration (Oral, Injectables, Others)
  • 5.2.3. By End-User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Locally Advanced Pancreatic Cancer Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Route of administration
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Locally Advanced Pancreatic Cancer Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Route of administration
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Locally Advanced Pancreatic Cancer Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Route of administration
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Locally Advanced Pancreatic Cancer Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Route of administration
      • 6.3.3.2.3. By End-User

7. Europe Locally Advanced Pancreatic Cancer Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Route of administration
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Locally Advanced Pancreatic Cancer Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Route of administration
      • 7.3.1.2.3. By End-User
  • 7.3.2. France Locally Advanced Pancreatic Cancer Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Route of administration
      • 7.3.2.2.3. By End-User
  • 7.3.3. United Kingdom Locally Advanced Pancreatic Cancer Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Route of administration
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Locally Advanced Pancreatic Cancer Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Route of administration
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Locally Advanced Pancreatic Cancer Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Route of administration
      • 7.3.5.2.3. By End-User

8. Asia Pacific Locally Advanced Pancreatic Cancer Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Route of administration
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Locally Advanced Pancreatic Cancer Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Route of administration
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Locally Advanced Pancreatic Cancer Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Route of administration
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan Locally Advanced Pancreatic Cancer Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Route of administration
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea Locally Advanced Pancreatic Cancer Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy
      • 8.3.4.2.2. By Route of administration
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Locally Advanced Pancreatic Cancer Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy
      • 8.3.5.2.2. By Route of administration
      • 8.3.5.2.3. By End-User

9. Middle East & Africa Locally Advanced Pancreatic Cancer Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Route of administration
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Locally Advanced Pancreatic Cancer Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Route of administration
      • 9.3.1.2.3. By End-User
  • 9.3.2. UAE Locally Advanced Pancreatic Cancer Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Route of administration
      • 9.3.2.2.3. By End-User
  • 9.3.3. South Africa Locally Advanced Pancreatic Cancer Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Route of administration
      • 9.3.3.2.3. By End-User

10. South America Locally Advanced Pancreatic Cancer Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Route of administration
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Locally Advanced Pancreatic Cancer Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Route of administration
      • 10.3.1.2.3. By End-User
  • 10.3.2. Colombia Locally Advanced Pancreatic Cancer Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Route of administration
      • 10.3.2.2.3. By End-User
  • 10.3.3. Argentina Locally Advanced Pancreatic Cancer Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Route of administration
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Locally Advanced Pancreatic Cancer Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Glaxosmithkline Plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co., Inc.
• 15.3. Bristol-Myers Squibb Company
• 15.4. Getwell
• 15.5. Ipsen Biopharmaceuticals, Inc.
• 15.6. Novartis Pharmaceuticals Corporation
• 15.7. Pfizer Inc.
• 15.8. Bayer HealthCare Pharmaceuticals, Inc.
• 15.9. Genentech USA, Inc.
• 15.10. AstraZeneca Plc

16. Strategic Recommendations

17. About Us & Disclaimer